{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:30:59Z","timestamp":1790728259133,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471085"],"award-info":[{"award-number":["82471085"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018634","name":"State Key Laboratory of Ophthalmology","doi-asserted-by":"publisher","award":["2025QZLH01"],"award-info":[{"award-number":["2025QZLH01"]}],"id":[{"id":"10.13039\/501100018634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.oret.2025.12.019","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T23:54:23Z","timestamp":1767052463000},"page":"532-542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Timing of Preoperative Anti-VEGF for Vitrectomy in Proliferative Diabetic Retinopathy"],"prefix":"10.1016","volume":"10","author":[{"given":"Jinlian","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5010-3931","authenticated-orcid":false,"given":"Gangan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxiu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2025.12.019_bib1","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/ICU.0000000000000946","article-title":"Recent advances in the management of proliferative diabetic retinopathy","volume":"34","author":"Pandit","year":"2023","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.019_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/aos.14482","article-title":"Long-term outcomes of vitrectomy for proliferative diabetic retinopathy","volume":"99","author":"Schreur","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.019_bib3","first-page":"CD008214","article-title":"Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy","volume":"5","author":"Dervenis","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.oret.2025.12.019_bib4","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s12886-020-01532-8","article-title":"Multiple factors in the prediction of risk of recurrent vitreous haemorrhage after sutureless vitrectomy for non-clearing vitreous haemorrhage in patients with diabetic retinopathy","volume":"20","author":"Ding","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.019_bib5","article-title":"Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy","volume":"2015","author":"Smith","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.oret.2025.12.019_bib6","article-title":"Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis","volume":"10","author":"Wang","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2025.12.019_bib7","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.survophthal.2021.03.001","article-title":"Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: a review","volume":"66","author":"Tan","year":"2021","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.019_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.oret.2024.08.004","article-title":"Anti-VEGF injections vs. panretinal photocoagulation laser therapy for proliferative diabetic retinopathy: a systematic review and meta-analysis","volume":"9","author":"Macaron","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2025.12.019_bib9","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1167\/iovs.17-22345","article-title":"Vitreous fibronectin and fibrinogen expression increased in eyes with proliferative diabetic retinopathy after intravitreal anti-VEGF therapy","volume":"58","author":"Wei","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2025.12.019_bib10","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/IAE.0000000000002633","article-title":"Anti-vascular endothelial growth factor therapy and risk of traction retinal detachment in eyes with proliferative diabetic retinopathy: pooled analysis of five DRCR retina network randomized clinical trials","volume":"40","author":"Bressler","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.12.019_bib11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/IAE.0000000000001952","article-title":"Apoptosis and angiofibrosis in diabetic tractional membranes after vascular endothelial growth factor inhibition: results of a prospective trial. Report No. 2","volume":"39","author":"Jiao","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.12.019_bib12","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.18240\/ijo.2022.10.09","article-title":"Optimal timing of preoperative intravitreal anti-VEGF injection for proliferative diabetic retinopathy patients","volume":"15","author":"Xu","year":"2022","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.019_bib13","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ophtha.2010.08.038","article-title":"Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications","volume":"118","author":"El-Sabagh","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2025.12.019_bib14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/s12886-024-03634-z","article-title":"Effect of anti-vascular endothelial growth factor on early-stage post-vitrectomy macular edema in patients with proliferative diabetic retinopathy","volume":"24","author":"Zhou","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.019_bib15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00417-008-0774-y","article-title":"Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)","volume":"246","author":"Rizzo","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.019_bib16","first-page":"709","article-title":"Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy","volume":"2","author":"El-Batarny","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.019_bib17","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/01.iae.0000225351.87205.69","article-title":"Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy","volume":"26","author":"Chen","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.oret.2025.12.019_bib18","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00417-010-1303-3","article-title":"Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy","volume":"248","author":"di Lauro","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.019_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1167\/iovs.65.4.37","article-title":"Short term effect of preoperative anti-VEGF on angiogenic and fibrotic profile of fibrovascular membranes of proliferative diabetic retinopathy","volume":"65","author":"Fadakar","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2025.12.019_bib20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1159\/000530231","article-title":"A systematic review and meta-analysis of clinical outcomes of small gauge vitrectomy with or without intravitreal anti-vascular endothelial growth factor agents pretreatment for proliferative diabetic retinopathy","volume":"66","author":"Pei","year":"2023","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.oret.2025.12.019_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bjo.2007.127142","article-title":"Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy","volume":"92","author":"Arevalo","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.019_bib22","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1164\/rccm.202305-0790CP","article-title":"Accounting for competing events when evaluating long-term outcomes in survivors of critical illness","volume":"208","author":"Angriman","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.oret.2025.12.019_bib23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12916-022-02349-6","article-title":"Predictive performance of a competing risk cardiovascular prediction tool CRISK compared to QRISK3 in older people and those with comorbidity: population cohort study","volume":"20","author":"Livingstone","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.oret.2025.12.019_bib24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.2009.2017","article-title":"Composite end points in randomized trials: there is no free lunch","volume":"303","author":"Tomlinson","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2025.12.019_bib25","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ajo.2017.12.009","article-title":"Preoperative bevacizumab administration in proliferative diabetic retinopathy patients undergoing vitrectomy: a randomized and controlled trial comparing interval variation","volume":"187","author":"Oli","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2025.12.019_bib26","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000493640","article-title":"Preoperative timing of intravitreal bevacizumab injection for proliferative diabetic retinopathy patients","volume":"60","author":"Feng","year":"2018","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.oret.2025.12.019_bib27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4239\/wjd.v4.i6.290","article-title":"Classification of diabetic retinopathy and diabetic macular edema","volume":"4","author":"Wu","year":"2013","journal-title":"World J Diabetes"},{"key":"10.1016\/j.oret.2025.12.019_bib28","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.oret.2025.12.019_bib29","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.oret.2025.12.019_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ydbio.2003.08.015","article-title":"Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival","volume":"264","author":"Darland","year":"2003","journal-title":"Dev Biol"},{"key":"10.1016\/j.oret.2025.12.019_bib31","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1242\/dev.126.7.1407","article-title":"VEGF deprivation-induced apoptosis is a component of programmed capillary regression","volume":"126","author":"Meeson","year":"1999","journal-title":"Development"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025006001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653025006001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:28:06Z","timestamp":1777602486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653025006001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2468653025006001"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2025.12.019","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Timing of Preoperative Anti-VEGF for Vitrectomy in Proliferative Diabetic Retinopathy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2025.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}